Healthy Nateglinide Pharmaceuticals For Diabetes Treatment 105816-04-4

Healthy Nateglinide Pharmaceuticals for the treatment of diabetes 105816-04-4

Nateglinide Quick detail

Product Name: Nateglinide
Synonyms: (-)-n-(trans-4-isopropylcyclohexanecarbonyl)-d-phenylalanine;ay4166;Nateglinide(H);trans-d-phenylalanin;trans-n-((4-(1-methylethyl)cyclohexyl)carbonyl)-d-phenylalanine;3-phenyl-2-(4-propan-2-ylcyclohexyl)carbonylamino-propanoic acid;A-4166;STARLIX
CAS: 105816-04-4
MF: C19H27NO3
MW: 317.42
Product Categories: Active Pharmaceutical Ingredients;API;APIs;Health & Beauty;Amino Acids & Derivatives;Intermediates & Fine Chemicals;Pharmaceuticals;Aromatics;STARLIX;Antidiabetic

Nateglinide Basic information

Packing: 1)Aluminum Foil Bag: 100g, 500g, 1Kg 2)Fiber Drum: 25Kg
Delivery Method: HKEMS, DHL, TNT, UPS, FEDEX, EMS, China Air Post etc.
Clearance Rate: 100% Custom Pass, Diguised Package and Safe Delivery
Delivery Time: 5-14 Working Days, Tracking Number Available
Payment Terms: T/T, MoneyGram, Western Union and Bitcoin
Origin: Hubei Province, China
Brand Name: Senwayer Brand
Production Capacity:  1000Kg/Month

Nateglinide Introduction:

Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the β cells. This depolarizes the β cells and causes voltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.

Nateglinide Function:

It can be used for diet control and /or exercise therapy for unsatisfactory control of blood glucose levels of type 2 diabets mellitus inpatients. It can be used as second-line drugs in treating typee 2 diabets mellitus inpatients with unsatisfactory control of blood glucose lecels as sulfonylureas and metformin bydrochloride.

Attention pls :

Those who are allergic to the chemicals, pregnant women, severe infection, severe trauma patients before and after surgery and diabetic coma and insulin-dependent diabetes patients disabled.

1. severe liver and kidney dysfunction, should be reduced or caution.

2. ischemic heart disease, pituitary and adrenal insufficiency deputy, diarrhea, vomiting and malnutrition in patients with caution.

3. Elderly patients and children with caution.

4. Use the regular testing of blood glucose, while other hypoglycemic drugs such as insulin sensitizers, α- glucosidase inhibitors in combination to adjust the dosage.

Related products: